Our Grantees

We support partners advancing patient-centered, innovative, evidence-based solutions to make the greatest impact on the crisis. Our grantees are educating health care providers, patients, and the public, developing innovative and effective treatment models, and informing payment and other policies to ensure access to care.

California Bridge Emergency Department Medications for Opioid Use Disorder Initiative

PI: Serena Clayton, PhD

Amount: $600,000
Timeline: March 2020 – 2022

The Public Health Institute is helping more than 100 hospitals across the U.S. build systems to deliver medications for opioid use disorder in the emergency department and refer patients to ongoing care, a strategy demonstrated to double the likelihood that patients with opioid use disorder will remain in treatment. Its California Bridge model emphasizes outreach, screening, treatment initiation, and the establishment of referral pathways.

Experiences of Opioid Treatment Programs in Delivering Telemedicine Services During the COVID-19 Pandemic

PI: Sarah Hunter, PhD

Amount: $61,098
Timeline: May – September 2020

Due to the COVID-19 pandemic, many opioid treatment programs (OTP) have had to rapidly transition from in-person care to telemedicine. Researchers at RAND will be conducting a qualitative study to explore providers’ experiences, the different modalities being offered, barriers encountered, and future plans. The study’s findings will inform the ongoing COVID-19 response and elicit lessons learned and policy recommendations for the future of OUD treatment.

Integrating Medications for Opioid Use Disorder into Primary Medical Care: Innovative Payer and Provider Strategies for Improving Treatment Engagement, Retention, Outcomes, and Disparities

PI: Stephen Crystal, PhD

Amount: $525,000
Timeline: February 2020 – 2022

New Jersey’s Medicaid program eliminated prior authorization requirements for buprenorphine, increased reimbursement for intake assessments, and now pays for navigation and peer support services. This evaluation will assess whether these changes have made care more accessible and improved treatment outcomes, helping to inform payers looking for ways to encourage primary care providers to offer medications for opioid use disorder.

COVID-19 Impact on Medications for Opioid Use Disorder Participants, Treatment, and Outcomes: Disparate COVID-19 Vulnerability and Impact of Unique Natural Experiments

PI: Stephen Crystal, PhD

Amount: $100,000
Timeline: July 2020 – 2022

During the pandemic, policymakers in New Jersey and other states have relaxed regulations for prescribing medications for opioid use disorder for Medicaid beneficiaries. This project would analyze Medicaid data and interviews with opioid treatment providers to see how the policy changes and resulting treatment adaptations, including increased telemedicine usage, longer methadone take-home doses, reduced drug screening, and reduced in-person counseling, have affected access to care and treatment outcomes.

Lowering Barriers, Saving Lives, Reclaiming Health: Integrating Medications for Opioid Use Disorder

PI: Lara Weinstein, MD, MPH, DrPH

Amount: $540,676
Timeline: February 2020 – 2022

Thomas Jefferson University’s low barrier medications for opioid use disorder program integrates primary and behavioral health care services, making it easier for the homeless and other marginalized populations to access treatment. In partnership with Project HOME and Pathways to Housing PA, it plans to expand access to the model, study its effectiveness, and offer learning opportunities for resident physicians, medical students, and physician assistant students.

Strategic Plans to Combat Opioid Use Disorder in the State of Alabama

PI: Li Li, MD, PhD

Amount: $410,266
Timeline: March 2020 – 2022

The University of Alabama at Birmingham is using a variety of tools — from educational modules and waiver training to telemedicine consultation — to prepare a cadre of primary care providers at their hospital and in a network of community health centers in Alabama to provide medications for opioid use disorder.